Literature DB >> 16007726

Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.

Doris R Siwak1, Shishir Shishodia, Bharat B Aggarwal, Razelle Kurzrock.   

Abstract

BACKGROUND: Nuclear factor-kappaB (NF-kappaB) plays a central role in cell survival and proliferation in human melanoma; therefore, the authors explored the possibility of exploiting NF-kappaB for melanoma treatment by using curcumin, an agent with known, potent, NF-kappaB-inhibitory activity and little toxicity in humans.
METHODS: Three melanoma cell lines (C32, G-361, and WM 266-4), all of which had B-raf mutations, were treated with curcumin, and the authors assessed its effects on viability ((3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide assay) and apoptosis (flow-cytometric analysis of annexin V/propidium iodide-stained cells). Curcumin-treated cells also were examined for NF-kappaB binding activity (electrophoretic mobility shift assay) and for the activity of its upstream regulator, IkappaB kinase (IKK) (immune complex kinase assay). In addition, relevant signaling, as reflected by B-Raf kinase activity (kinase cascade assay), and steady-state levels of activated, downstream effectors, as reflected by mitogen-activated signal-regulated protein kinase (MEK), extracellular signal-regulated protein kinase (ERK), and Akt phosphorylation levels (immunoblots), were assessed.
RESULTS: Curcumin treatment decreased cell viability of all 3 cell lines in a dose-dependent manner (50% inhibitory concentration = 6.1-7.7 microM) and induced apoptosis. NF-kappaB and IKK were active constitutively in all melanoma cell lines examined, and curcumin, under apoptosis-inducing conditions, down-regulated NF-kappaB and IKK activities. However, curcumin did not inhibit the activities of B-Raf, MEK, or ERK, and Akt phosphorylation was enhanced. Furthermore, in the presence of curcumin, the Akt inhibitor 1L-6-hydroxymethyl-chiro-inositol 2-[(R)-2-O-methyl-3-O-octadecylcarbonate] no longer suppressed Akt phosphorylation.
CONCLUSIONS: Curcumin has potent antiproliferative and proapoptotic effects in melanoma cells. These effects were associated with the suppression of NF-kappaB and IKK activities but were independent of the B-Raf/MEK/ERK and Akt pathways.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16007726     DOI: 10.1002/cncr.21216

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  57 in total

1.  Curcuminoids activate p38 MAP kinases and promote UVB-dependent signalling in keratinocytes.

Authors:  Elias E Ayli; Susanne Dugas-Breit; Weijie Li; Christine Marshall; Liang Zhao; Marc Meulener; Thomas Griffin; Joel M Gelfand; John T Seykora
Journal:  Exp Dermatol       Date:  2010-04-20       Impact factor: 3.960

2.  Novel Curcumin-Resveratrol Solid Nanoparticles Synergistically Inhibit Proliferation of Melanoma Cells.

Authors:  Gayathri Heenatigala Palliyage; Noor Hussein; Michael Mimlitz; Catherine Weeder; Marya Hassan A Alnasser; Somnath Singh; Andrew Ekpenyong; Amit K Tiwari; Harsh Chauhan
Journal:  Pharm Res       Date:  2021-05-12       Impact factor: 4.200

3.  Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.

Authors:  Jyoti Nautiyal; Sanjeev Banerjee; Shailender S Kanwar; Yingjie Yu; Bhaumik B Patel; Fazlul H Sarkar; Adhip P N Majumdar
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

4.  Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs.

Authors:  Ardith W El-Kareh; Rachel E Labes; Timothy W Secomb
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

5.  Can curcumin and its analogs be a new treatment option in cancer therapy?

Authors:  H Mirzaei; M J M Khoi; M Azizi; M Goodarzi
Journal:  Cancer Gene Ther       Date:  2016-11       Impact factor: 5.987

6.  Active curcumin nanoparticles formed from a volatile microemulsion template.

Authors:  K Margulis; S Srinivasan; M J Ware; H D Summers; B Godin; S Magdassi
Journal:  J Mater Chem B       Date:  2014       Impact factor: 6.331

7.  Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells.

Authors:  Matthew Miller; Shenglin Chen; Jeffrey Woodliff; Sanjay Kansra
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

Review 8.  Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases.

Authors:  Bharat B Aggarwal; Kuzhuvelil B Harikumar
Journal:  Int J Biochem Cell Biol       Date:  2008-07-09       Impact factor: 5.085

9.  The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.

Authors:  Matthew A Bill; James R Fuchs; Chenglong Li; Jennifer Yui; Courtney Bakan; Don M Benson; Eric B Schwartz; Dalia Abdelhamid; Jiayuh Lin; Dale G Hoyt; Stacey L Fossey; Gregory S Young; William E Carson; Pui-Kai Li; Gregory B Lesinski
Journal:  Mol Cancer       Date:  2010-06-25       Impact factor: 27.401

10.  Overexpression of the ATP binding cassette gene ABCA1 determines resistance to Curcumin in M14 melanoma cells.

Authors:  Beatrice E Bachmeier; Cristina M Iancu; Peter H Killian; Emanuel Kronski; Valentina Mirisola; Giovanna Angelini; Marianne Jochum; Andreas G Nerlich; Ulrich Pfeffer
Journal:  Mol Cancer       Date:  2009-12-23       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.